Page 1

Contact : Investors : Traci McCarty BioMarin Pharmaceutical Inc. ( 415 ) 455-7558 • Exhibit 99.1 BIOMARIN Media : Debra Charlesworth BioMarin Pharmaceutical Inc. ( 415 ) 455-7451 BioMarin Announces Second Quarter 2021 Financial Results and Corporate Updates Total Revenues Grew 17 % in the Second Quarter 2021 Compared to Second Quarter 2020 Raising Full - year 2021 Financial Guidance • Marketing Authorization Application ( MAA ) for Valoctocogene Roxaparvovec , for the Treatment of Severe Hemophilia A , Validated by European Medicines Agency ; CHMP Opinion Expected First Half 2022 Positive CHMP Opinion Received in Europe for VOXZOGOTM for the Treatment of Children with Achondroplasia from Age 2 until Growth Plates Close ; European Commission Decision expected in the Third Quarter 2021 • FDA Review of VOXZOGO Proceeding ; PDUFA Target Action Date November 20 , 2021 BioMarin to Showcase Development Pipeline at R & D Day November 2021 Financial Highlights ( in millions of U.S. dollars , except per share data , unaudited ) Three Months Ended June 30 , 2021 2020 % Change 2021 Six Months Ended June 30 , 2020 % Change Total Revenues $ 501.7 $ 429.5 17 % $ 987.7 $ 931.6 6 % Net Product Revenues Marketed by BioMarin ( 1 ) $ 458.6 $ 386.8 19 % $ 876.3 $ 820.1 7 % Vimizim Net Product Revenues Naglazyme Net Product Revenues Kuvan Net Product Revenues Palynziq Net Product Revenues $ Brineura Net Product Revenues Aldurazyme Net Product Revenues GAAP Net Income ( Loss ) GAAP Net Income ( Loss ) per Share - Basic GAAP Net Income ( Loss ) per Share - Diluted Non - GAAP Income ( 2 ) $ EA EA EA EA EA EA $ 171.7 $ 116.7 47 % $ 329.9 $ 253.9 30 % $ 118.8 $ 81.0 47 % $ 226.1 $ 195.3 16 % $ 78.8 $ 122.6 ( 36 ) % $ 149.6 $ 244.6 ( 39 ) % 59.0 $ 40.7 45 % $ 113.0 $ 75.3 50 % $ 30.3 $ 25.8 17 % $ 57.7 $ 49.8 16 % 28.1 $ 32.3 ( 13 ) % $ 78.1 $ 88.0 ( 11 ) % $ EA EA EA EA $ 12.9 $ ( 29.2 ) $ 0.07 $ ( 0.16 ) $ $ 0.07 $ 97.8 ( 0.16 ) EA $ 57.4 SA SASA A $ 30.3 $ 52.2 0.17 $ 0.29 $ 0.16 202.1 EA EA . $ 0.28 $ 173.9 Cash , cash equivalents and investments June 30 , 2021 December 31 , 2020 $ 1,473.6 $ 1,350.9 ( 1 ) Net Product Revenues Marketed by BioMarin is the sum of revenues from Vimizim , Kuvan , Naglazyme , Palynziq , Brineura for the three and six months ended June 30 , 2021 and includes Firdapse for the six months ended June 30 , 2020 , each calculated in accordance with Generally Accepted Accounting Principles in the United States ( U.S. GAAP ) . Sanofi Genzyme ( Genzyme ) is BioMarin's sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties . Refer to page 10 for a table showing Net Product Revenues by product . In January 2020 , BioMarin divested the Firdapse assets to a third party in a sale transaction . The sale is reflected in the Company's consolidated financial statements for the first quarter ended March 31 , 2020 ; as a result of the transaction BioMarin no longer recognizes Net Product Revenues from Firdapse . 1